- Home
- SRG vs ABEO Comparison
SRG vs ABEO Comparison
Compare SRG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ABEO
- Stock Information
- Founded
- SRG 2014
- ABEO N/A
- Country
- SRG United States
- ABEO United States
- Employees
- SRG N/A
- ABEO N/A
- Industry
- SRG Real Estate Investment Trusts
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ABEO Health Care
- Exchange
- SRG Nasdaq
- ABEO Nasdaq
- Market Cap
- SRG 254.9M
- ABEO 277.6M
- IPO Year
- SRG 2015
- ABEO 1980
- Fundamental
- Price
- SRG $4.46
- ABEO $6.22
- Analyst Decision
- SRG
- ABEO Strong Buy
- Analyst Count
- SRG 0
- ABEO 3
- Target Price
- SRG N/A
- ABEO $18.00
- AVG Volume (30 Days)
- SRG 216.1K
- ABEO 289.4K
- Earning Date
- SRG 11-06-2024
- ABEO 11-11-2024
- Dividend Yield
- SRG N/A
- ABEO N/A
- EPS Growth
- SRG N/A
- ABEO N/A
- EPS
- SRG N/A
- ABEO N/A
- Revenue
- SRG $59,030,000.00
- ABEO N/A
- Revenue This Year
- SRG N/A
- ABEO N/A
- Revenue Next Year
- SRG N/A
- ABEO $7,097.06
- P/E Ratio
- SRG N/A
- ABEO N/A
- Revenue Growth
- SRG 274.65
- ABEO 147.52
- 52 Week Low
- SRG $3.63
- ABEO $3.05
- 52 Week High
- SRG $9.87
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- SRG 46.05
- ABEO 55.30
- Support Level
- SRG $4.17
- ABEO $6.39
- Resistance Level
- SRG $4.44
- ABEO $6.74
- Average True Range (ATR)
- SRG 0.12
- ABEO 0.29
- MACD
- SRG -0.02
- ABEO -0.03
- Stochastic Oscillator
- SRG 41.03
- ABEO 48.99
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.